323 results
Page 2 of 17
8-K
EX-99.1
qiy0 zulng4nx
27 Jun 23
Amicus Therapeutics Announces Approval and Launch of New Pompe Disease Therapy in the European Union
7:01am
8-K
EX-10.1
j2yqu
12 May 23
Entry into a Material Definitive Agreement
5:08pm
8-K
EX-99.1
wepw hsfjhyle63q0
10 May 23
Amicus Therapeutics Announces First Quarter 2023 Financial Results and Corporate Updates
7:01am
8-K
EX-99.1
wqol4l f4egnl0g9e
26 Apr 23
Amicus Therapeutics Receives Positive CHMP Opinion for Opfolda® (miglustat) for Late-Onset Pompe Disease
2:04pm
8-K
EX-10.1
6kobv
28 Dec 22
Entry into a Material Definitive Agreement
5:00pm
8-K
EX-1.1
ftdzz7jim
7 Nov 22
Entry into a Material Definitive Agreement
7:22am
424B5
xyx cf1f3jvfygovjvk
7 Nov 22
Prospectus supplement for primary offering
7:11am
8-K
EX-99.1
p1nhe 0zo8wbd8j4y
7 Nov 22
Amicus Therapeutics Announces Third Quarter 2022 Financial Results and Corporate Updates
7:01am
8-K
EX-99.1
ynkd9c 8q
4 Aug 22
Amicus Therapeutics Announces Second Quarter 2022 Financial Results
7:01am
8-K
3dkdcx637ttadg
1 Aug 22
Departure of Directors or Certain Officers
5:10pm
8-K
EX-10.1
5n3qnhlrjas 5o8
1 Aug 22
Departure of Directors or Certain Officers
5:10pm
8-K/A
EX-99.1
wpeu5
9 May 22
Amicus Therapeutics Announces First Quarter 2022 Financial Results
12:54pm
8-K
EX-99.1
27nsm2rbx447mr2
9 May 22
Amicus Therapeutics Announces First Quarter 2022 Financial Results
7:00am